Families nationwide face rising health insurance costs as Affordable Care Act subsidies near expiration, with premiums and deductibles projected to increase amid congressional inaction.
Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.
Roche's anti-CD20 antibody improved renal response and allowed for lower corticosteroid use in the phase III REGENCY trial, offering a twice-yearly maintenance option after initial dosing.